Fennec Pharmaceuticals Inc. (FRX.TO)
| Previous Close | 12.65 |
| Open | 12.46 |
| Bid | 12.83 x 0 |
| Ask | 12.92 x 0 |
| Day's Range | 12.46 - 12.65 |
| 52 Week Range | 9.27 - 15.43 |
| Volume | |
| Avg. Volume | 283 |
| Market Cap | 342.814M |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.82 |
| Earnings Date | May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireFennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May
Simply Wall St.Those who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
GuruFocus.comInsider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC)
Fennec Pharmaceuticals Inc (NASDAQ:FENC), a biopharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients, has reported a significant insider sell transaction.
